OA10572A - Nigella sativa as a medicinal treatment - Google Patents

Nigella sativa as a medicinal treatment Download PDF

Info

Publication number: OA10572A
Authority: OA; OAPI
Prior art keywords: cells; extract; sativa; per day; administered
Prior art date: 1993-08-25

Application number

OA60779A

Other languages

English (en)

Inventor

Rajko D Medenica

Original Assignee

Rajko D Medenica

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-25

Filing date

1996-02-23

Publication date

2002-06-03

1996-02-23 Application filed by Rajko D Medenica filed Critical Rajko D Medenica

2002-06-03 Publication of OA10572A publication Critical patent/OA10572A/en

Links

244000090896 Nigella sativa Species 0.000 title claims abstract description 90
235000016698 Nigella sativa Nutrition 0.000 title claims description 16
238000011282 treatment Methods 0.000 title claims description 14
239000001711 nigella sativa Substances 0.000 title claims description 13
239000000284 extract Substances 0.000 claims abstract description 85
206010028980 Neoplasm Diseases 0.000 claims abstract description 52
230000000694 effects Effects 0.000 claims abstract description 24
201000011510 cancer Diseases 0.000 claims abstract description 20
230000001965 increasing effect Effects 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
230000036737 immune function Effects 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 227
238000000034 method Methods 0.000 claims description 62
239000000203 mixture Substances 0.000 claims description 40
241000711975 Vesicular stomatitis virus Species 0.000 claims description 34
108010050904 Interferons Proteins 0.000 claims description 31
102000014150 Interferons Human genes 0.000 claims description 31
210000001185 bone marrow Anatomy 0.000 claims description 31
229940079322 interferon Drugs 0.000 claims description 28
210000004881 tumor cell Anatomy 0.000 claims description 21
241000700605 Viruses Species 0.000 claims description 17
210000003719 b-lymphocyte Anatomy 0.000 claims description 17
230000000120 cytopathologic effect Effects 0.000 claims description 12
241000282412 Homo Species 0.000 claims description 11
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 10
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 10
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 9
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 9
239000000427 antigen Substances 0.000 claims description 9
108091007433 antigens Proteins 0.000 claims description 9
102000036639 antigens Human genes 0.000 claims description 9
239000003112 inhibitor Substances 0.000 claims description 8
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 5
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 5
230000004936 stimulating effect Effects 0.000 claims description 4
206010009944 Colon cancer Diseases 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
210000004882 non-tumor cell Anatomy 0.000 claims description 3
238000011319 anticancer therapy Methods 0.000 claims description 2
201000001441 melanoma Diseases 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
230000003213 activating effect Effects 0.000 claims 1
230000001093 anti-cancer Effects 0.000 abstract description 6
238000002512 chemotherapy Methods 0.000 abstract description 5
229920001817 Agar Polymers 0.000 description 37
239000008272 agar Substances 0.000 description 37
238000003556 assay Methods 0.000 description 36
239000000419 plant extract Substances 0.000 description 34
239000000243 solution Substances 0.000 description 29
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
108010002350 Interleukin-2 Proteins 0.000 description 24
102000000588 Interleukin-2 Human genes 0.000 description 24
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 21
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 20
238000010790 dilution Methods 0.000 description 20
239000012895 dilution Substances 0.000 description 20
210000002798 bone marrow cell Anatomy 0.000 description 19
238000011534 incubation Methods 0.000 description 19
238000012360 testing method Methods 0.000 description 19
210000004369 blood Anatomy 0.000 description 18
239000008280 blood Substances 0.000 description 18
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 18
241000283690 Bos taurus Species 0.000 description 17
239000012980 RPMI-1640 medium Substances 0.000 description 16
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
210000000265 leukocyte Anatomy 0.000 description 15
239000000463 material Substances 0.000 description 15
239000012153 distilled water Substances 0.000 description 14
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 13
239000003102 growth factor Substances 0.000 description 13
239000003814 drug Substances 0.000 description 12
239000002609 medium Substances 0.000 description 12
239000006285 cell suspension Substances 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
239000006228 supernatant Substances 0.000 description 11
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 10
238000004364 calculation method Methods 0.000 description 10
230000001332 colony forming effect Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000000523 sample Substances 0.000 description 10
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 9
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 9
229930182816 L-glutamine Natural products 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 9
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 8
230000012010 growth Effects 0.000 description 8
229920000669 heparin Polymers 0.000 description 8
239000000367 immunologic factor Substances 0.000 description 8
229960005322 streptomycin Drugs 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
244000304337 Cuminum cyminum Species 0.000 description 7
241000196324 Embryophyta Species 0.000 description 7
229930182555 Penicillin Natural products 0.000 description 7
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
239000011521 glass Substances 0.000 description 7
238000011365 human tumor colony assay Methods 0.000 description 7
229940049954 penicillin Drugs 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000013630 prepared media Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
CECDPVOEINSAQG-UHFFFAOYSA-N 2-(2-hydroxyphenyl)-4,5-dihydrothiazole-4-carboxylic acid Chemical compound OC(=O)C1CSC(C=2C(=CC=CC=2)O)=N1 CECDPVOEINSAQG-UHFFFAOYSA-N 0.000 description 6
108010066676 Abrin Proteins 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
230000000259 anti-tumor effect Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000003472 neutralizing effect Effects 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
239000001044 red dye Substances 0.000 description 6
239000006163 transport media Substances 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
210000002808 connective tissue Anatomy 0.000 description 5
230000002519 immonomodulatory effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000002616 plasmapheresis Methods 0.000 description 5
229960001471 sodium selenite Drugs 0.000 description 5
239000011781 sodium selenite Substances 0.000 description 5
230000035899 viability Effects 0.000 description 5
239000012224 working solution Substances 0.000 description 5
240000007241 Agrostis stolonifera Species 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
235000007129 Cuminum cyminum Nutrition 0.000 description 4
108010078049 Interferon alpha-2 Proteins 0.000 description 4
229940099550 actimmune Drugs 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
239000000645 desinfectant Substances 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
108010042414 interferon gamma-1b Proteins 0.000 description 4
230000002934 lysing effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000013610 patient sample Substances 0.000 description 4
238000011045 prefiltration Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
235000013599 spices Nutrition 0.000 description 4
239000012192 staining solution Substances 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
238000003860 storage Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
206010003445 Ascites Diseases 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
108010074604 Epoetin Alfa Proteins 0.000 description 3
108010014173 Factor X Proteins 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 3
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
108010074328 Interferon-gamma Proteins 0.000 description 3
102000008070 Interferon-gamma Human genes 0.000 description 3
102100031586 Leukocyte antigen CD37 Human genes 0.000 description 3
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
235000007413 Nigella arvensis Nutrition 0.000 description 3
241000206607 Porphyra umbilicalis Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
102000005157 Somatostatin Human genes 0.000 description 3
108010056088 Somatostatin Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
210000001691 amnion Anatomy 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000035572 chemosensitivity Effects 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
238000009826 distribution Methods 0.000 description 3
229940089118 epogen Drugs 0.000 description 3
229940044627 gamma-interferon Drugs 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
210000004976 peripheral blood cell Anatomy 0.000 description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 3
229960000553 somatostatin Drugs 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000004565 tumor cell growth Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
244000178870 Lavandula angustifolia Species 0.000 description 2
235000010663 Lavandula angustifolia Nutrition 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
206010025538 Malignant ascites Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010067482 No adverse event Diseases 0.000 description 2
238000000944 Soxhlet extraction Methods 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
210000003567 ascitic fluid Anatomy 0.000 description 2
229940064804 betadine Drugs 0.000 description 2
238000004820 blood count Methods 0.000 description 2
238000009835 boiling Methods 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
230000002026 carminative effect Effects 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
230000035602 clotting Effects 0.000 description 2
239000012531 culture fluid Substances 0.000 description 2
230000000249 desinfective effect Effects 0.000 description 2
FPRGRROJPRIHJP-UHFFFAOYSA-N dithymoquinone Chemical compound O=C1C(C(C)C)=CC(=O)C2(C)C1C1(C)C(=O)C=C(C(C)C)C(=O)C12 FPRGRROJPRIHJP-UHFFFAOYSA-N 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
230000001882 diuretic effect Effects 0.000 description 2
230000003028 elevating effect Effects 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000004110 gluconeogenesis Effects 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
239000012676 herbal extract Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000001102 lavandula vera Substances 0.000 description 2
235000018219 lavender Nutrition 0.000 description 2
239000002523 lectin Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000009630 liquid culture Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000003607 modifier Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
230000002476 tumorcidal effect Effects 0.000 description 2
CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
RYAUSSKQMZRMAI-YESZJQIVSA-N (S)-fenpropimorph Chemical compound C([C@@H](C)CC=1C=CC(=CC=1)C(C)(C)C)N1C[C@H](C)O[C@H](C)C1 RYAUSSKQMZRMAI-YESZJQIVSA-N 0.000 description 1
241001474033 Acar Species 0.000 description 1
244000144927 Aloe barbadensis Species 0.000 description 1
235000002961 Aloe barbadensis Nutrition 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
101100077213 Caenorhabditis elegans mlc-2 gene Proteins 0.000 description 1
241000070928 Calligonum comosum Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241001425477 Dysdercus Species 0.000 description 1
101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
102100031939 Erythropoietin Human genes 0.000 description 1
244000228957 Ferula foetida Species 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
102100039350 Interferon alpha-7 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
240000002853 Nelumbo nucifera Species 0.000 description 1
235000006508 Nelumbo nucifera Nutrition 0.000 description 1
235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
240000008338 Nigella arvensis Species 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
241000218201 Ranunculaceae Species 0.000 description 1
101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
206010040007 Sense of oppression Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000812633 Varicus Species 0.000 description 1
101100108191 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) add gene Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003217 anti-cancerogenic effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000007640 basal medium Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
230000002279 cholagogic effect Effects 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000003021 clonogenic effect Effects 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
235000013409 condiments Nutrition 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000004734 cutaneous carcinogenesis Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000009982 effect on human Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
229940124600 folk medicine Drugs 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000010005 growth-factor like effect Effects 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000003525 myelopoietic effect Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
238000005502 peroxidation Methods 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
239000010832 regulated medical waste Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000004576 sand Substances 0.000 description 1
229940072272 sandostatin Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960001814 trypan blue Drugs 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

OA60779A 1993-08-25 1996-02-23 Nigella sativa as a medicinal treatment OA10572A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/111,631 US5482711A (en)	1993-08-25	1993-08-25	Use of Nigella sativa to increase immune function

Publications (1)

Publication Number	Publication Date
OA10572A true OA10572A (en)	2002-06-03

Family

ID=22339582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60779A OA10572A (en)	1993-08-25	1996-02-23	Nigella sativa as a medicinal treatment

Country Status (12)

Country	Link
US (2)	US5482711A (de)
EP (1)	EP0804212B1 (de)
AT (1)	ATE392902T1 (de)
AU (1)	AU7868794A (de)
BR (1)	BR9407362A (de)
CA (1)	CA2169956A1 (de)
DE (1)	DE69435091D1 (de)
HU (1)	HU226319B1 (de)
OA (1)	OA10572A (de)
PL (1)	PL182890B1 (de)
SI (1)	SI9420054B (de)
WO (1)	WO1995005839A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE1009579A5 (fr) *	1996-07-04	1997-05-06	Ismail Mohamed Tejeddine	Systeme vibratoire de protection contre les nuisances des radiations emises par les ecrans de visualisation et/ou autres sources de radiations, d'equilibrage bio-energetique et d'harmonisation geobiologique ou de bio-assainissement des locaux de travail et des habitations.
US6042834A (en) *	1997-01-29	2000-03-28	Baraka; Mohamed Wasif	Herbal composition for diabetes and method of treatment
EP0970183B1 (de) *	1997-03-20	2005-10-05	Allen C. Barnes	Mikropathologischer abdruck von eines patienten auf basis von vollblut
KR100239879B1 (ko) *	1997-11-05	2000-02-01	김상조	간암 예방 및 치료용 생약제
US6440448B1 (en)	1998-03-16	2002-08-27	Joseph Intelisano	Food supplement/herbal composition for health enhancement
US6231866B1 (en)	1998-04-30	2001-05-15	Douglas G. Mann	Infused vegetable, fruit, herb, and/or seed fiber product and dietary supplements containing same
US6218434B1 (en)	1998-05-28	2001-04-17	University Of Kentucky Research Foundation	Use of the naturally-occurring quinones thymoquinone and dithymoquinone as antineoplastic and cytotoxic agents
DE19844022C1 (de) *	1998-09-25	2000-05-25	Sherif Sabry Ragab Mekkawi	Verwendung von eisenbindenden Glycoproteinen und/oder 10-Hydroxy-2-decensäure in Verbindung mit Thymochinon zur Behandlung von AIDS
GB2348132B (en) *	1999-03-02	2004-08-04	Nedaa Abdul-Ghani Nasif	Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
GB9904777D0 (en)	1999-03-02	1999-04-28	Nassief Nida A	Novel method, an asthma therapy that act on eosinophils and/or t-lymphocytes
GB2347859B (en) *	1999-03-19	2004-02-25	Yasin Nazir Karim Yakub	Herbal compositions
RU2172322C1 (ru)	1999-12-27	2001-08-20	Энтофарм Ко., Лтд.	Аллофероны-иммуномодулирующие пептиды
US6948494B1 (en) *	2000-05-10	2005-09-27	Innovative Devices, Llc.	Medicament container with same side airflow inlet and outlet and method of use
AU2003209674A1 (en) *	2002-03-12	2003-09-22	Council Of Scientific And Industrial Research	Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
AU2003281259A1 (en) *	2002-07-09	2004-01-23	Shifa Abdo Saeed Ahmed Al Azazi	Natural herbal antibiotic for the treatment of the infections of the upper respiratory system and various diseases in the body
US7744929B2 (en) *	2003-09-15	2010-06-29	Ambotan Pharma, Llc	Botanical drug compositions for treatments of liver and immunological disorders
US7722906B2 (en) *	2004-03-26	2010-05-25	Biopharm Research & Development Corporation Limited	Polyunsaturated fatty acid fractions of Nigella sativa L. seeds
US20050214393A1 (en) *	2004-03-26	2005-09-29	Osama Kandil	Lipid fraction of Nigella sativa L. seeds
US20090175970A1 (en) *	2005-01-26	2009-07-09	Veritron Limited	Stabilized Plant Extract and Its Therapeutic Use
GB0501654D0 (en) *	2005-01-26	2005-03-02	Veritron Ltd	Stabilised plant extract
WO2008021990A2 (en)	2006-08-10	2008-02-21	Barnes Allen C	Portable biological testing device and method
FR2922109B1 (fr)	2007-10-16	2010-08-20	Bruno Eto	Composition pharmaceutique ou dietetique pour inhiber l'absorption intestinale du sucre.
CN109776669A (zh) *	2018-12-29	2019-05-21	广州动物园	虎γ干扰素及其表达基因、制备方法和应用
US11260097B2 (en)	2020-07-06	2022-03-01	COVImmune Pharma LLC	Immunomodulatory composition to treat and/or prevent COVID-19 illness
US12295982B2 (en)	2021-09-17	2025-05-13	Nasoil, S.A. De C.V.	Synergistic composition to treat respiratory diseases and strengthen the immune system to fight other diseases and procedure to manufacture such composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4687761A (en) *	1985-05-09	1987-08-18	Yaguang Liu	Pharmaceutical composition for increasing immunity and decreasing side effects of anticancer chemotherapy
US4945115A (en) *	1985-05-09	1990-07-31	Yaguang Liu	Process for preparing ferulic acid

1993
- 1993-08-25 US US08/111,631 patent/US5482711A/en not_active Expired - Lifetime
1994
- 1994-08-25 EP EP94929736A patent/EP0804212B1/de not_active Expired - Lifetime
- 1994-08-25 HU HU9600442A patent/HU226319B1/hu not_active IP Right Cessation
- 1994-08-25 CA CA002169956A patent/CA2169956A1/en not_active Abandoned
- 1994-08-25 BR BR9407362A patent/BR9407362A/pt not_active Application Discontinuation
- 1994-08-25 WO PCT/US1994/009660 patent/WO1995005839A1/en not_active Ceased
- 1994-08-25 SI SI9420054A patent/SI9420054B/sl not_active IP Right Cessation
- 1994-08-25 PL PL94313223A patent/PL182890B1/pl not_active IP Right Cessation
- 1994-08-25 AT AT94929736T patent/ATE392902T1/de not_active IP Right Cessation
- 1994-08-25 DE DE69435091T patent/DE69435091D1/de not_active Expired - Lifetime
- 1994-08-25 AU AU78687/94A patent/AU7868794A/en not_active Abandoned
1995
- 1995-05-03 US US08/433,603 patent/US5653981A/en not_active Expired - Lifetime
1996
- 1996-02-23 OA OA60779A patent/OA10572A/en unknown

Also Published As

Publication number	Publication date
EP0804212B1 (de)	2008-04-23
AU7868794A (en)	1995-03-21
ATE392902T1 (de)	2008-05-15
PL182890B1 (pl)	2002-03-29
HU9600442D0 (en)	1996-04-29
SI9420054B (sl)	2008-10-31
HUT74226A (en)	1996-11-28
SI9420054A (en)	1997-02-28
US5653981A (en)	1997-08-05
CA2169956A1 (en)	1995-02-26
PL313223A1 (en)	1996-06-10
DE69435091D1 (de)	2008-06-05
EP0804212A2 (de)	1997-11-05
WO1995005839A1 (en)	1995-03-02
US5482711A (en)	1996-01-09
BR9407362A (pt)	1996-04-23
HU226319B1 (en)	2008-08-28

Publication	Publication Date	Title
US5482711A (en)	1996-01-09	Use of Nigella sativa to increase immune function
Nantz et al.	2012	Supplementation with aged garlic extract improves both NK and γδ-T cell function and reduces the severity of cold and flu symptoms: a randomized, double-blind, placebo-controlled nutrition intervention
Jorum et al.	2016	Haematological effects of dichloromethane-methanolic leaf extracts of Carissa edulis (Forssk.) Vahl in normal rat models
Guida et al.	2016	Thymoquinone rescues T lymphocytes from gamma irradiation-induced apoptosis and exhaustion by modulating pro-inflammatory cytokine levels and PD-1, Bax, and Bcl-2 signaling
Takagi et al.	2005	Immune activation and radioprotection by propolis
Bazarbachi et al.	2000	Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma
Faisal et al.	1989	Natural cytotoxicity of tilapia leucocytes
Gupta et al.	2016	Anti-inflammatory and anti-microbial activities of aqueous leaves extract of Butea frondosa
Kimang’a et al.	2016	Safety and analgesic properties of ethanolic extracts of Toddalia Asiatica (L) Lam.(Rutaceae) used for central and peripheral pain management among the east African ethnic communities
Marques-Santos et al.	2023	Comparative evaluation of plant extract effects on peritoneal, medullary and J774 cells. G8 macrophages
Gupta et al.	2014	In vitro anti-inflammatory activity of root aqueous extract of Mesua ferrea in human whole blood and peripheral blood mononuclear cells using flow cytometry.
Schuberth et al.	2002	Flow cytometric testing of immunological effects of a phytomedicinal combination (equimun) and its compounds on bovine leucocytes
Aldi et al.	2019	Effect of ethanol from extract of Tapak Liman leaves (Elephantopus scaber Linn.) on hematopoiesis of anemia mice
Kasim et al.	2015	Haematopoietic and safety study of methanolic extract of the bark of Trema orientalis (L.) Blume Fam. Ulmaceae
Irinmwinuwa et al.	2022	Investigation into the effect of ethanol leaf extract and fractions of Justicia Secunda on platelets and WBC counts in mice
Lang et al.	1981	Effect of Histamine Receptor Blocking on Human Antibody‐dependent Cell‐mediated Cytotoxicity
Obeagu	2018	Evaluation of effect of Crude Methanol Tetrapleura Tetraptera (TTE) on Hematological Parameters of Albino Rats
Ebhohimen et al.	2024	Assessment of the Antiplasmodial and Haematoprotective Potential of a Polyherbal Extract of Azadirachta indica, Mangifera indica, and Persea americana Leaves in Mice Infected with Plasmodium berghei.
Djati et al.	2017	Tapak liman (Elephantopus scaber L) extract–induced CD4+ and CD8+ differentiation from hematopoietic stem cells and progenitor cell proliferation in mice (Mus musculus L)
Shokan et al.	2024	Effect of the complex extract from Rumex plants on quantitative parameters of blood cells and bone marrow in vivo
Al-Nuaimi et al.	2025	The Promotive Effects of Punica granatum Seed Extract on Hematological, Cardiovascular, and Reproductive Biomarkers in Rabbits
Szymaniec et al.	1987	Human seminal plasma suppresses lymphocyte responses in vitro in serum-free medium
Onyishi et al.	2021	Comparative anti-malaria potentials of leaf and root extracts of Alstonia boonei on the haematological indices of mice infected with Plasmodium Berghei
Nagaraj et al.	2018	Evaluation of invitro cytotoxic activity of parts of Murraya koenigii (curry) plant on human peripheral blood mononuclear cells
Stein	2000	Toxicology of mistletoe and their components